The headquarters of the Ministry of Health.
the Medicines Committee between Medicines He decided Merging general financing 18 new drugsThose that cover serious diseases such as Cancer, rare diseases, resistance infections or muscle neurological disorders. This commitment enhances patients’ access to innovative treatments within the national health system (SNS) through new financing reports promoted by the Ministry of Health.
Among the new additions Elucirem (Gadopiclenol)A means of contrast between the magnetic resonance that will be funded for adults and children for two years in situations in which the image is not sufficient. The activity similar to other means of contrast and its interest in asking for a lower dose of Gadolinio may be constructed in its decision.
In the field of emergency medicine, Agilus (dantroleeno) It is approved for funding as a basic treatment for malignant temperature, which is fatal complications in anesthesia. The recognition of its role was an urgent antidote to its inclusion.
He also financed Despurano Paxter (Despurano)Although it is in a limited way: it will only be used in situations where another anesthesia cannot be used, following the environmental restrictions of European organization on excellent gases.
The list also includes innovations in muscle neurological diseases Rystiggo (Rozanolixizumab),, Which will be funded as a supplement in a generalized miaasthenia gravis, which covers a need so far without an alternative to patients with positive antibodies.
In the oncology area, SNS will allow access to it From Zina (Talazoprib) In conjunction with Enzalutamide to treat metastatic prostate cancer, wrapping in patients with BRCA1/2 mutations. Likewise, (Talquetamab) may be funded for adults who suffer from several myeloma that receive at least three previous treatments, with a scheme that includes the maximum cost per patient.
Large cellular lymph nodes will also have a new option: Epcoritamab reactionWhich showed benefits in patients in relapse or thermal into two or more lines of treatment.
In the treatment of solid cancers, TEVIMBRA (TISLELIZUMAB) It will be funded for several indicators in lung, esophagus and stomach cancer, indicating a significant improvement in survival against standard treatments.
Acute rabbinical leukemia will get the IDD FLT3 mutation Kukargin In conjunction with chemotherapy and monotheism. However, its use will not be funded as a mono maintenance treatment.
It was also combined Fruzaqla (Fruquintinib) For colon and rectal cancer spread in patients who have exhausted other treatments, as a modest improvement in survival has been proven.
Pediatrics and three negative diseases
In diseases pediatricsFrom medicines, Spexotras (TRAMETINIB) Y Finlee (Dabrafeenib)It will be funded in a composition for the treatment of low and high glial tumors in children with Braf V600E mutation, a great alternative to traditional chemotherapy.
In the face of serious fungal infections, they were combined Rezyo (Rezafungina) To treat invasive candidiasis, the evaluation of its weekly dose that reduces the care burden positively.
SNS will also enhance its arsenal against multi -resistant bacteria with two groups of antibiotics: Emblaveo (aztreeonam/avibactam) and Exblifep (CEFEPIMA/ANEZOBACTAM). Both will be largely funded due to serious infections without other alternatives and under the supervision of arch equipment in hospitals.
On the other side, Not all the medications analyzed the necessary support for financing have achieved general. Hemgenix (Etranacogén Dezaparvovec), innovative genetic therapy of hemophilia B, due to doubts about its cost -cost effectiveness and uncertainty of its long -term interest. finance Camuzius (MAVACAMTEN), which is directed to huge padded heart intransigence, and Velsipity (Etrasimod), for ulcerative colitis, especially for the reasons for clinical comparison and economic sustainability.
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
